First-generation EGFR tyrosine kinase inhibitors, including gefitinib and erlotinib, are the first-line treatment against advanced non-small cell lung cancers with EGFR activating mutations, especially in Asians, females, never smokers, and/or patients with adenocarcinoma [16]. Here, EGFR is linked to non-small cell lung carcinoma.